Key facts
- Some African nations are rejecting US health aid packages due to conditions attached.
- Ghana, Zambia, and Zimbabwe have cited data protection and economic linkage concerns.
- The US frames its foreign assistance as strategic capital to advance American interests.
- Kenya's $2.5bn health deal involves significant contributions from both the US and the East African nation.
- Concerns include US access to patient data, biological resources, and preferential treatment for US firms.
Some African nations are resisting new US health aid packages offered by the Trump administration, citing concerns over data protection, economic conditions, and the prioritization of American strategic interests. While the US aims to build self-reliant health systems through direct government agreements, countries like Ghana, Zambia, and Zimbabwe have pushed back against the terms.
Ghana rejected a proposed $109 million health deal in April due to concerns about the scope of data required and the protection of Ghanaian data sovereignty. Zambia's Foreign Minister Mulambo Haimbe criticized the US for attempting to link health funding to a separate agreement granting Washington access to critical minerals, stating the government wished to negotiate them separately.
Zimbabwe also cited concerns about requests for medical data, presumably for sharing with US pharmaceutical companies, as the reason for rejecting a deal. The State Department has emphasized that US foreign assistance is strategic capital intended to advance American interests, expecting recipient nations to take US strategic and commercial priorities seriously.
Kenya, however, signed a landmark $2.5 billion deal in December, with the US contributing $1.6 billion and Kenya pledging $850 million over five years. This deal, though initially delayed by activists, represents the administration's shift towards direct government partnerships, moving away from traditional donor-NGO relationships. The policy document explicitly states the global health foreign assistance program is a strategic mechanism to further bilateral interests, including a promise to prioritize US pharmaceuticals and medical firms.